<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01229865</url>
  </required_header>
  <id_info>
    <org_study_id>VB-111-103</org_study_id>
    <nct_id>NCT01229865</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of VB-111 in Subjects With Advanced Differentiated Thyroid Cancer</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vascular Biogenics Ltd. operating as VBL Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vascular Biogenics Ltd. operating as VBL Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the safety and evaluate the response of VB-111 on&#xD;
      DTC.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective response</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Differential Thyroid Cancer</condition>
  <arm_group>
    <arm_group_label>VB-111</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>antiangiogenic and vascular disruptive agent</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VB-111</intervention_name>
    <arm_group_label>VB-111</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically or cytologically confirmed advanced DTC (papillary, follicular, Hurthle&#xD;
             cell);&#xD;
&#xD;
          2. Absence of sensitivity to therapeutic radioiodine;&#xD;
&#xD;
          3. Measurable disease, defined as at least one non-bony lesion that can be accurately&#xD;
             measured in at least one dimension as confirmed with spiral CT scan&#xD;
&#xD;
          4. Life expectancy &gt;3 months; ECOG performance status (PS) 0, 1, or 2; Karnofsky&#xD;
             performance status of ≥60%;&#xD;
&#xD;
          5. Subjects with a normal/acceptable hematological profile&#xD;
&#xD;
          6. Subjects with adequate renal function&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Presence of any of the following:&#xD;
&#xD;
               -  Radiotherapy or chemotherapy &lt;4 weeks prior to baseline visit; (Concurrent and/or&#xD;
                  prior therapy with octreotide will be allowed, provided tumor progression on this&#xD;
                  therapy has been demonstrated; Concurrent and/or prior therapy with&#xD;
                  biphosphonates will be allowed)&#xD;
&#xD;
               -  Radiotherapy to ≥25% of bone marrow;&#xD;
&#xD;
          2. Major surgery &lt;4 weeks prior to baseline visit;&#xD;
&#xD;
          3. Any other ongoing investigational agents within 4 weeks before dosing;&#xD;
&#xD;
          4. Subjects who suffered from an acute cardiac event within the last 12 months, including&#xD;
             myocardial infarction, cardiac arrythmia, admission for unstable angina, cardiac&#xD;
             angioplasty, or stenting;&#xD;
&#xD;
          5. QTc prolongation (defined as QTc interval ≥500 msecs) or other significant ECG&#xD;
             abnormalities (e.g. frequent ventricular ectopy, evidence of ongoing myocardial&#xD;
             ischemia);&#xD;
&#xD;
          6. Subjects with active vascular disease, either myocardial or peripheral;&#xD;
&#xD;
          7. Subjects with proliferative and/or vascular retinopathy;&#xD;
&#xD;
          8. Subjects with known active liver disease (alcoholic, drug/toxin induced, genetic, or&#xD;
             autoimmune) other than related to tumor metastases;&#xD;
&#xD;
          9. Subjects with known CNS metastatic disease (Exception: Subjects with treated CNS&#xD;
             metastases stable by radiographic examinations &gt;6 months after definitive therapy&#xD;
             administered, are eligible);&#xD;
&#xD;
         10. Subjects testing positive to one of the following viruses: HIV, HBV or HCV;&#xD;
&#xD;
         11. Any of the following conditions:&#xD;
&#xD;
               -  Serious or non-healing wound, ulcer, or bone fracture;&#xD;
&#xD;
               -  History of abdominal fistula, gastro-intestinal perforation, active&#xD;
                  diverticulitis, intra-abdominal abscess or gastro-intestinal tract bleeding&#xD;
                  within 6 months of dosing;&#xD;
&#xD;
               -  Any history of cerebrovascular accident (CVA) within 6 months of dosing;&#xD;
&#xD;
               -  Current use of therapeutic warfarin (Note: Low molecular weight heparin and&#xD;
                  prophylactic low-dose warfarin [INR&lt;1.2 X ULN] are permitted);&#xD;
&#xD;
               -  History of bleeding disorder, including subjects with hemophilia, disseminated&#xD;
                  intravascular coagulation (DIC), or any other abnormality of coagulation&#xD;
                  potentially predisposing subjects to bleeding;&#xD;
&#xD;
               -  Poorly controlled depression or anxiety disorder, or recent (within the previous&#xD;
                  6 months) suicidal ideation;&#xD;
&#xD;
         12. Subjects with an ongoing requirement for immunosuppressive treatment, including the&#xD;
             use of glucocorticoids or cyclosporin, or with a history of chronic use of any such&#xD;
             medication within the last 4 weeks before dosing;&#xD;
&#xD;
         13. Uncontrolled intercurrent illness including, but not limited to ongoing or active&#xD;
             infection, or psychiatric illness/social situations that would limit compliance with&#xD;
             study requirements.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <study_first_submitted>October 26, 2010</study_first_submitted>
  <study_first_submitted_qc>October 26, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 28, 2010</study_first_posted>
  <last_update_submitted>October 22, 2018</last_update_submitted>
  <last_update_submitted_qc>October 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thyroid Neoplasms</mesh_term>
    <mesh_term>Thyroid Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

